Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease Nov. 13, 2020 9:17 AM ET Albireo Pharma, Inc. (ALBO) By: Mamta Mayani , SA News Editor About Albireo Pharma Inc. Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. Five analysts have issued estimates for Albireo Pharma’s earnings, with the lowest sales estimate coming in at $1.84 million and the highest estimate coming in at $2.56 million. An Albireo Pharma news release notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat. 39.77 0.00 (0.00%)After hours: 4:15PM EST, Subscribe to Premium to view Fair Value for ALBO. 11/16: ALBIREO PHARMA: New Phase 3 Data at AASLD Show Durable Response to Odevixibat i.. AQ. In the last year Albireo Pharma saw its revenue grow by 327%. View real-time stock prices and stock quotes for a full financial overview. View real-time stock prices and stock quotes for a full financial overview. Albireo Pharma, Inc., ehemals Biodel Inc., ist ein biopharmazeutisches Spezialunternehmen. Albireo Pharma Inc is a development-stage pharmaceutical company. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.51) by $0.45. Albireo Pharma Inc ALBO Morningstar Rating Rating as of Oct 15, 2020. Find the latest Albireo Pharma, Inc. (ALBO) stock quote, history, news and other vital information to help you with your stock trading and investing. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. News zur ALBIREO PHARMA AKTIE und aktueller Realtime-Aktienkurs Albireo Pharma … Seite 95 der Diskussion 'Albireo Pharma Inc. Aktie' vom 07.11.2016 im w:o-Forum 'Biotech'. It engages in the research and development of drug reformulation technology. Investors in Albireo Pharma, Inc. (NASDAQ:ALBO) had a good week, as its shares rose 4.1% to close at US$32.84 following the release of its quarterly results. Stable Share Price: ALBO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week. ALBIREO PHARMA AKTIE (ISIN: US01345P1066): Realtime-Kurs der ALBIREO PHARMA Aktie, Dividenden-Rendite und Termine, aktuelle Nachrichten ⇒ Die nächsten Kursziele. Aktuelle Börsenkurse, den Aktien-Chart, Kursinformationen und die Kursentwicklung bzw. Albireo’s clinical pipeline includes three mid to late-stage product candidates that are designed to act locally to potentially restore normal bile acid levels and are being developed to treat diseases and disorders associated with irregularities in bile acid biology. JOIN ALBIREO. Sep. Biotechnologie-Branche. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. In other Albireo Pharma news, insider Martha J. Carter sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Tuesday, November, 10th. The stock was sold at an average price of $38.97, for a total transaction of $389,700.00. Equal Opportunity Employer: Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. Progressive Familial Intrahepatic Cholestasis (PFIC), Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC, New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease, Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences, Albireo Reports Q3 2020 Financial Results and Provides Business Update, Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers, Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting, Albireo Recognizes PFIC Awareness Day 2020, Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Albireo Prices Public Offering of 4,000,000 Shares of Common Stock, Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock. Albireo Pharma (ALBO) Investor Presentation - Slideshow: 13.11. GlobeNewsWire - 2 months ago. Price to Earnings Ratio vs. the Market. Shares of Albireo Pharma (NASDAQ: ALBO) are up by 41.4% as of 11:49 a.m. EDT on Tuesday, after soaring by as much as 79% earlier today. Company profile page for Albireo Pharma Inc including stock price, company news, press releases, executives, board members, and contact information 04:30p: Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixiba.. GL. Forward-Looking Statements Find out more. Price to Earnings Ratio vs. Sector Jan Mattsson, Ph.D. Chief Scientific Officer, Managing Director (Sweden), and Co-Founder About Albireo Pharma Inc. Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. Get the latest Albireo Pharma, Inc. (ALBO) stock news and headlines to help you in your trading and investing decisions. S . On December 8, 2020, Albireo Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial intrahepatic … Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 8 at 5:39 PM: Albireo Pharma, Inc. (ALBO) Q2 2020 Earnings Call Transcript fool.com - August 7 at 6:48 PM: Albireo Pharma EPS beats by $0.28, beats on revenue seekingalpha.com - August 6 at 12:35 PM Odevixibat is a … ALBIREO PHARMA, INC. : News, information and stories for ALBIREO PHARMA, INC. | Nasdaq: ALBO | Nasdaq JOIN ALBIREO. Albireo Pharma News & Analysen: Hier finden Sie die News & Analysen-Seite für den Wert Albireo Pharma Branche nach Marktkapitalisierung. 11/13 : ALBIREO PHARMA, INC.: Other Events, Financial … ALBIREO PHARMA, INC. - 8-K, Current Report: 13.11. Pipeline. ALBO | Complete Albireo Pharma Inc. stock news by MarketWatch. Es konzentriert sich auf die Entwicklung und Vermarktung von Gallensäuremodulatoren zur Behandlung von pädiatrischen Lebererkrankungen und Magen-Darm-Erkrankungen, bei denen ein unsachgemäßer Fluss oder eine unsachgemäße Aufnahme von Gallenflüssigkeit schwere medizinische Erkrankungen … Albireo Pharma zählt ... 06.02.19 , Aktiennews. A high-level overview of Albireo Pharma, Inc. (ALBO) stock. Albireo PharmaWas steht jetzt noch aus, ? Meet the Albireo Pharma enterprise team. All news about ALBIREO PHARMA, INC. 10/15: ALBIREO PHARMA, INC.: Change in Directors or Principal Officers (form 8-K) AQ The Motley Fool - 2 months ago. Albireo Pharma Aktie (BDQM) Branche: : (WKN: A2DF99 ISIN: US01345P1066 ) Kurs mit Realtime Chart Alle Entwicklungen, Kommentare und News auf BörsenNEWS.de live verfolgen. Because Albireo Pharma made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. ALBIREO PHARMA, INC.: 8-K Report (SEC Filing) FORM 8-K... 09.09.20 - 16:31. According to our data, Albireo Pharma, Inc. has a market capitalization of US$264m, and paid its CEO total annual compensation worth US$3.6m over the year to December 2018. It's been a good week for Albireo Pharma, Inc. (NASDAQ:ALBO) shareholders, because the company has just released its latest third-quarter results, and the shares gained 4.1% to US$32.84.Revenues of US$2.1m crushed expectations, although expenses also blew out, with the company reporting a statutory loss per share of US$1.96, 30% bigger than analysts expected. Albireo Pharma Aktie: WKN A2DF99 - ISIN US01345P1066 - Aktueller Aktienkurs, Charts, Nachrichten und Termine zu Albireo Pharma. Most relevant news about ALBIREO PHARMA, INC. 10/23: Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting: GL. Aktien Check 09. BOSTON — December 8, 2020 — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the … About Albireo Who We Are. and EU primary and secondary endpoints with high ly   statistically significant reductions in serum bile acids and pruritus   - - Interim results from long-term extension study   show sustained improvements in serum bile acids, pruritus - - Improvements in growth, BOSTON , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London, -   P ositive P hase 3 d ata for   o devixibat in PFIC with filings on track for no later than early 202 1 - -   Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and novel bile acid modulator A3907 at AASLD - -   Raised $160 million in gross proceeds in. The biopharmaceutical company had revenue of $2.13 million for the quarter, compared to analysts' expectations of $1.90 million. Currency in USD, Trade prices are not sourced from all markets, The Big Electric Vehicle Story Everyone's Missing. Why Albireo Pharma Stock Is Skyrocketing Today. Item 8.01 Other Events. News und Analysen zu Albireo Pharma 21.02.19 , Aktiennews. Albireo Pharma News & Analysen: Hier finden Sie die News & Analysen-Seite für den Wert Albireo Pharma An RSS aggregator can be a stand-alone application, or a plug-in for another program you already use, such as Microsoft Outlook.Some web browsers, such as Firefox and Safari RSS, have RSS readers built in.There are also online aggregators, websites such as My Yahoo that allow you to customize them by adding RSS feeds. View the latest Albireo Pharma Inc. (ALBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal. ALBIREO PHARMA INC (A2DF99 | US01345P1066) mit aktuellem Aktienkurs, Charts, News und Analysen. Earnings for Albireo Pharma are expected to decrease in the coming year, from ($7.45) to ($8.43) per share. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Real time Albireo Pharma, Inc. (ALBO) stock price quote, stock graph, news & analysis. An der Heimatbörse NASDAQ CM notiert Albireo Pharma per 21.02.2019, 14:46 Uhr bei 25,97 USD. © 2020 Verizon Media. BOSTON , Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Shares of Albireo Pharma (NASDAQ:ALBO) are up by 41.4% as of 11:49 a.m. EDT on Tuesday, after soaring by as much as 79% earlier today. Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today. Share Price & News. -   Final PEDFIC 1 and interim PEDFIC 2 results   accepted   at AASLD’s The Liver Meeting 2020   - - PEDFIC   1 and   PEDFIC 2 : largest global Phase 3 in children with PFIC types 1,   2   &   3   - -   Two abstracts to be presented on new pipeline compound   - BOSTON , Nov. - Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- - Scientific leadership demonstrate s c ompany’s   commitment to increase understanding of   rare pediatric cholestatic liver disease s and reduce burden   of illness - BOSTON , Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases BOSTON , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing, BOSTON , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’s common, BOSTON , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common. Find the latest Albireo Pharma, Inc. (ALBO) stock quote, history, news and other vital information to help you with your stock trading and investing. Albireo Pharma Aktie (ALBO) mit Realtime-Aktienkurs, Chart, Bilanzinformationen, Dividenden, historischen Daten, aktuellen News und Analysen. Latest Share Price and Events. Contact |  Terms of Use  |  Privacy Policy, - Data   on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment , validates Marketing Authorization Application for odevixibat with o rphan d esignation and access to PRIority MEdicines (PRIME) - -   FDA has granted o devixibat   F ast T, - PEDFIC 1   meets   both U . ALBO, Albireo Pharma Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Albireo Pharma Inc Stock Quote: ALBO Stock News, Quotes, Analysis | Investors.com WKN: A2DF99, ISIN: US01345P1066, Albireo Pharma ▸ Aktueller Aktienkurs, Chart, Kennzahlen & News anzeigen - Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment, validates Marketing Authorization Application for odevixibat with... | … News zur Aktie Albireo Pharma (WKN A2DF99, ISIN US01345P1066). BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten publ... 09.09.20 - 22:38. BOSTON , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stock. Albireo Pharma News: Die neuesten Meldungen zur Albireo Pharma Aktie im Überblick – alle aktuellen Nachrichten, Analysen, Überblicke rund um Albireo Pharma. Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences. Find the latest news headlines from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Find the latest news headlines from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Albireo Pharma Albireo Pharma: SD-Jubiläumsrakete liefert +115%. ALBO | Complete Albireo Pharma Inc. stock news by MarketWatch. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. For more information on Albireo, please visit www.albireopharma.com. 10/05: ALBIREO PHARMA: Reports Inducement Grant under Nasdaq Listing Rule 5635: AQ. Albireo Pharma Inc ALBO ... Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive News. Shareholders of unprofitable companies usually expect strong revenue growth. How do I use RSS? How has Albireo Pharma's share price performed over time and what events caused price changes? 10/23: ALBIREO PHARMA: Announces Presentations at NASPGHAN 2020 Annual Meeting: AQ. Albireo PharmaLohnt sich das wirklich, ? Analysts predict that Albireo Pharma, Inc. (NASDAQ:ALBO) will announce $2.15 million in sales for the current fiscal quarter, Zacks Investment Research reports. Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. Albireo Pharma Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. News & Analysen zu Albireo Pharma. The company reported positive data from a clinical trial. While investors are obsessed with Tesla's surge, legendary investor Whitney Tilson says an even bigger EV story will provide the highest gains. All rights reserved. 10/05: ALBIREO PHARMA… Equal Opportunity Employer: Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. Company profile page for Albireo Pharma Inc including stock price, company news, press releases, executives, board members, and contact information All news about ALBIREO PHARMA, INC. 04:37p: ALBIREO PHARMA, INC.: Other Events, Financial Statements and Exhibits (form 8-K.. AQ. To make use of RSS, you'll need an RSS reader, or aggregator. 10/06: ALBIREO PHARMA: Recognizes PFIC Awareness Day 2020: AQ. The P/E ratio of Albireo Pharma is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.